Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bayer A.G. (OTC: BAYRY).

Full DD Report for BAYRY

You must become a subscriber to view this report.

Recent News from (OTC: BAYRY)

Exelixis Will Continue It's Stride Despite Cotellic Combo Failure In Colorectal Cancer
Recently, Exelixis ( EXEL ) and its partner Roche ( RHHBY ) announced that the phase 3 study treating patients with colorectal cancer did not succeed . It was announced that the combination of Cotellic with Tecentriq failed to improve overall survival ((OS)) in this patient population. ...
Source: SeekingAlpha
Date: May, 14 2018 01:53
Roche's doublet therapy fails to beat Bayer's Stivarga in late-stage CRC study
A Phase 3 clinical trial, IMblaze370 , evaluating Roche ( OTCQX:RHHBY ) unit Genentech's doublet therapy of COTELLIC (cobimetinib) + TECENTRIQ (atezolizumab) in patients with treatment-resistant late-stage colorectal cancer (CRC) failed to achieve the primary endpoint of a statistical...
Source: SeekingAlpha
Date: May, 10 2018 07:07
The Ongoing Loxo Thesis, Part 1: Loxo's Rising Star
Note: Subscribers to the Total Pharma Tracker got an early look at this article, as well as access exclusive notes offering my opinions on the end game for these companies. You can try for free and join this conversation! Loxo Oncology ( LOXO ) is one of those companies that biotech in...
Source: SeekingAlpha
Date: May, 10 2018 02:44
Iterum Therapeutics Plans $92 Million IPO
Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci...
Source: SeekingAlpha
Date: May, 07 2018 12:02
Monsanto CEO Grant to step down upon closing of Bayer deal
Monsanto (NYSE: MON ) says Chairman and CEO Hugh Grant plans to leave upon the closing of Bayer's ( OTCPK:BAYRY ) acquisition of the company. More news on: Monsanto Company, Bayer A.G. ADR, Merger & acquisition news, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 09:19
Kiniksa Pharmaceuticals Files For $100 Million IPO
Quick Take Kiniksa Pharmaceuticals (KNSA) intends to sell Class A shares for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapies for a range of inflammatory and autoimmune diseases in cardiac and skin conditions. ...
Source: SeekingAlpha
Date: May, 04 2018 12:33
Monsanto appeals to India's Supreme Court over GM cotton patents
Monsanto ( MON -0.1% ) says it has appealed to India’s Supreme Court against last month's ruling by the Delhi High Court that it cannot claim patents on its genetically modified cotton seeds. More news on: Monsanto Company, Bayer A.G. ADR, DowDuPont Inc., Commodities news, R...
Source: SeekingAlpha
Date: May, 04 2018 10:56
Regeneron: Like Apple In 2016, Hated But Great - And Ready To Roll
Back story - The strong outperformance of large cap biotechs ( IBB ) and probably junior biotechs ( XBI ) from about 2010 to mid-2015 may be analogous to the run of "tech" from late 1994 to tech's mid-1998 peak: long, strong and somewhat overdone, but not a real bubble. And, set to rec...
Source: SeekingAlpha
Date: May, 04 2018 10:15
Bayer trades flat even after cutting full-year earnings guidance
Bayer ( OTCPK:BAYRY , OTCPK:BAYZF ) shares are little changed after the company says it expects adjusted EBITDA to decline by a low single-digit percentage to less than €35B ($42B) for FY 2018, rather than coming in flat as previously forecast. More news on: Bayer A.G. ADR, Bayer...
Source: SeekingAlpha
Date: May, 03 2018 09:42
Sprint And T-Mobile Unite Forces (Wall Street Breakfast Podcast)
Get today's Wall Street Breakfast in podcast form to listen on the go. Today’s top stories: Sprint (S) and T-Mobile (TMUS) have agreed on a merger; personal consumption expenditures are expected to be 2 percent; and in the U.K. J Sainsbury (JSAIY) and Walmart’s Asda (WMT) hav...
Source: SeekingAlpha
Date: April, 30 2018 10:54


About Bayer A.G. (OTC: BAYRY)

Logo for Bayer A.G. (OTC: BAYRY)

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. lt br / gt lt br / gt Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non agricultural pest control. Bayer MaterialScience AG is a renowned supplier of high performance materials and innovative system solutions used in a wide range of products for everyday life. lt br / gt lt br / gt The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible corporate citizen, Economy, ecology and social responsibility are corporate policy objectives of equal rank. In fiscal , More information is available on the Internet at




Current Management

  • Dr. Marijn Dekkers / CEO
  • Werner Wenning / CFO
  • Martin Eisenhauer / Securities Counsel
  • Peter Dahlhoff / IR

Current Share Structure


    Daily Technical Chart for (OTC: BAYRY)

    Daily Technical Chart for (OTC: BAYRY)

    Stay tuned for daily updates and more on (OTC: BAYRY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: BAYRY)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    The Subway Trader



    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BAYRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BAYRY and does not buy, sell, or trade any shares of BAYRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: